


# Accepted Manuscript

Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of *Helicobacter pylori* Infection in a Randomized Controlled Trial

Ping-I. Hsu, Feng-Woei Tsay, David Y. Graham, Tzung-Jiun Tsai, Kuo-Wang Tsai, John Y. Kao, Nan-Jing Peng, Chao-Hung Kuo, Sung-Shuo Kao, Huay-Min Wang, Te-Fu Lin, Deng-Chyang Wu



PII: S1542-3565(18)30328-8  
DOI: [10.1016/j.cgh.2018.03.031](https://doi.org/10.1016/j.cgh.2018.03.031)  
Reference: YJCGH 55770

To appear in: *Clinical Gastroenterology and Hepatology*  
Accepted Date: 16 March 2018

Please cite this article as: Hsu P-I, Tsay F-W, Graham DY, Tsai T-J, Tsai K-W, Kao JY, Peng N-J, Kuo C-H, Kao S-S, Wang H-M, Lin T-F, Wu D-C, On behalf of the Taiwan Acid-related Disease (TARD) Study Group, Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of *Helicobacter pylori* Infection in a Randomized Controlled Trial, *Clinical Gastroenterology and Hepatology* (2018), doi: 10.1016/j.cgh.2018.03.031.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title:** Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of *Helicobacter pylori* Infection in a Randomized Controlled Trial

**SHORT TITLE:** Reverse hybrid & bismuth therapy for *H pylori* infection

**AUTHORS:** Ping-I Hsu,<sup>1\*</sup> Feng-Woei Tsay,<sup>1</sup> David Y. Graham,<sup>2</sup> Tzung-Jiun Tsai,<sup>1</sup> Kuo-Wang Tsai,<sup>3</sup> John Y. Kao,<sup>4</sup> Nan-Jing Peng,<sup>5</sup> Chao-Hung Kuo,<sup>6</sup> Sung-Shuo Kao,<sup>1</sup> Huay-Min Wang,<sup>1</sup> Te-Fu Lin,<sup>1</sup> Deng-Chyang Wu,<sup>6</sup> On behalf of the Taiwan Acid-related Disease (TARD) Study Group

**AUTHORS' AFFILIATIONS:** <sup>1</sup>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan; <sup>2</sup>Department of Medicine, Veterans Affairs Medical Center, and Baylor College of Medicine, Houston, Texas, USA; <sup>3</sup>Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; <sup>4</sup> Department of Internal Medicine, Division of Gastroenterology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA; <sup>5</sup>Department of Nuclear Medicine, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan; <sup>6</sup>Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

**GRAND SUPPORT:** The study was funded by the Ministry of Science and Technology, Executive Yuan, ROC, Taiwan (Grant Number: MOST 104-2314-B-075B-001-MY2) and the Kaohsiung Veterans General Hospital (Grant Number: VGHKS104-062).

**ABBREVIATIONS:** ACG, American College of Gastroenterology; CI, confidence interval;

Download English Version:

<https://daneshyari.com/en/article/8724721>

Download Persian Version:

<https://daneshyari.com/article/8724721>

[Daneshyari.com](https://daneshyari.com)